Clinical Trial Update: A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating acalabrutinib in combination with rituximab and either bendamustine or venetoclax in patients with mantle cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Rituxan (rituximab)
• Treanda (Bendamustine)
• Venclexta (venetoclax)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Mantle Cell Lymphoma (MCL) | Phase 1 | Status: ACTIVE_NOT_RECRUITING